First Cancer Diagnostic Test Based On Rosetta Genomics’ Proprietary MicroRNA Technology Receives Regulatory Approval
July 23rd, 2008 | by admin |
Rosetta Genomics, Ltd. (NASDQ: ROSG) announces that the first molecular test based on Rosetta Genomics’ proprietary microRNA technology, developed and validated by Columbia University Medical Center (CUMC), has been approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program.
Original post by Allergy News From Medical News Today
Stumble it!
